Surface the importer cohort in a target destination for an API you supply. Aggregated cohort share, current origin mix, and the regulatory profile of who they buy from today.
The Brazil rosuvastatin lane cleared $10.2M of declared inbound API trade in 2024 across 165 shipments. The active exporter cohort is 13 firms with top-3 share of 85.5%, indicating a tractable lane: not a single anchor, room for a credible new entrant. The importer cohort is concentrated among Brazilian generics formulators with ANVISA-registered marketing authorisations on rosuvastatin formulations.
| # | Molecule | Lane (origin → BR) | 2024 inbound | Importer cohort pattern | Top exporter share |
|---|---|---|---|---|---|
| 1 | Rosuvastatin | BR · ANVISA-registered formulators | 10 $M | 13 active exporters | Top-3 85.5% · HHI 3462 |
| 2 | Metoprolol | BR · cardiovascular formulators | 18 $M | 5 active exporters | Top-3 99.8% · HHI 6790 |
| 3 | Esomeprazole | BR · GI formulators | 13 $M | 8 active exporters | Top-3 99.6% · HHI 9052 |
| 4 | Duloxetine | BR · CNS formulators | 12 $M | 7 active exporters | Top-3 99.6% |
| 5 | Venlafaxine | BR · CNS formulators | 11 $M | 11 active exporters | Top-3 96.1% |
| 6 | Amlodipine | BR · cardiovascular formulators | 7 $M | 9 active exporters | Top-3 98.9% |
| 7 | Metformin | BR · diabetes formulators | 6 $M | 11 active exporters | Top-3 99.3% |
| 8 | Clarithromycin | BR · antibiotic formulators | 6 $M | 5 active exporters | Top-3 98.7% |
| 9 | Pregabalin | BR · CNS formulators | 5 $M | 12 active exporters | Top-3 75.6% · softer |
| 10 | Pantoprazole | BR · GI formulators | 4 $M | 12 active exporters | Top-3 66.1% · softer |
Destination country plus the API you supply. The AI agent scopes the inbound trade flow and the active exporter cohort already serving the lane.
Aggregate inbound volume, origin-mix share, lane concentration, and the regulatory profile (ANVISA, FDA, MHRA equivalents) of the buyer cohort. All references aggregated.
Citation-anchored cohort summary plus a generated outreach prompt tailored to the lane competitiveness shape. Hand off to BD.
Counterparty-anonymised cohort view. A supplier sees the shape of the buyer pool (concentrated vs distributed) without ever surfacing a named buyer-to-seller transaction.
PharmaDB never surfaces named transactions. The cohort view is the supply-side artifact that respects the trade-data disclaimer at the query layer.
Top-3 share and HHI tell you whether the lane is anchored (hard entry) or distributed (tractable entry). Sequence outreach by tractability.
Each row routes to a generated outreach prompt that references the cohort pattern. No named buyer surfaced; the prompt focuses on the molecule, lane size, and supply-side value proposition.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Rosuvastatin API inbound · 2024 · top-3 exporter share per destination · lower is more tractable.
The outbound buyer cohort view is the supplier-side BD primitive. A supplier evaluating a destination needs the lane reality (size, growth, exporter density) and the buyer cohort shape (concentrated vs distributed), grounded in trade flows but anonymised at the counterparty layer. PharmaDB enforces that boundary at the query layer. The view is molecule_country_flow; the join is to lane_competitiveness. Refresh cadence is weekly.
No. The trade-data disclaimer prohibits surfacing named buyer-to-seller transactions. PharmaDB surfaces the importer cohort as an aggregate: how many buyers, how concentrated, what regulatory profile. The outreach prompt is grounded in the cohort shape, not a single buyer name.
All declared importers of the molecule into the destination over the rolling 24-month window. The view aggregates volume per buyer-class without exposing per-buyer detail. Counterparty anonymisation is enforced at the query layer.
A top-3 share below 80% means no single trio of suppliers anchors the lane. The cohort is distributed enough that a credible new entrant can place initial volume without dislodging an incumbent. The pregabalin and pantoprazole rows into Brazil are examples (75-76% and 66%).
Because the supplier-side BD motion is not 'call buyer X.' It is 'enter this lane against this cohort shape with this regulatory differentiator.' The cohort view gives the supplier the lane reality; the BD team prospects against the regulator-registered formulator set.
Yes. The view is built on aggregated trade declarations that are themselves public in most jurisdictions, then aggregated further into cohort shape at the schema layer. PharmaDB's policy is stricter than the source data: no named transactions, ever.
Weekly. Trade aggregates refresh every week. The cohort shape recomputes on every refresh; the catalog row carries the exact computation timestamp.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.